In pediatric leukemia, JAK2 inhibitors could be particularly valuable for patients with JAK2 mutations or dysregulated JAK-STAT signaling, such as those with ALL, AML, and CML. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.